Why a treatment name is not enough for a pituitary surgical review
A surgical team reviewing a pituitary tumour needs to understand the current state of the disease, not just the history of what was tried. The phrase 'I had surgery in 2022' or 'I took cabergoline' does not indicate whether the tumour shrank, whether hormone levels normalised, whether vision improved or worsened, or whether the tumour later regrew. Each of those outcomes changes how a surgeon thinks about the case.
Pituitary tumours sit close to the optic nerves and the normal pituitary gland. Endoscopic transsphenoidal surgery reaches this region through the nose, so the surgical approach itself is influenced by the size and position of the tumour and by whether vision is affected. Hormone and vision issues can be relevant to assessment. A previous treatment result is therefore not background information; it is part of the current clinical picture.
When you describe previous treatment, the useful unit is not the drug or operation name but the measured result: a hormone value with its date and reference range, an imaging finding with the modality and date, or a visual field result with the date and the testing method. Without those, the receiving team cannot tell whether the disease is controlled, progressing or stable.
What to include for each previous treatment episode
For every treatment episode, aim to answer four questions in writing: what was done, when it was done, what was measured afterwards, and what the result was. If you had surgery, state the date, the approach used if you know it, and what the postoperative imaging and hormone tests showed. If you took medication, state the drug name, the dose, the dates started and stopped, and the hormone levels before and after.
If you had radiotherapy, state the type, the date, the target and the follow-up imaging and hormone results since then. If you are currently on hormone replacement, state which hormones, at what dose, and when the dose was last changed. Do not adjust any medication on your own before a review; the prescribing clinician manages that.
A simple table or a short structured summary is more useful than a long narrative. The goal is for a clinician to see the trajectory at a glance: what was tried, what happened, and where things stand now.
- Treatment name, type and dates
- What was measured afterwards and by which method
- The actual result, with units and reference range where available
- Current hormone replacement or suppressive medication, with doses
- Any change in vision, headaches or other symptoms, with dates
Endocrine results: the numbers, dates and units that matter
Pituitary disease is assessed largely through hormone measurements, and those measurements only make sense with their context. A prolactin level of 80 means different things depending on the assay, the units and the reference range used by the laboratory. When you send endocrine reports, include the original laboratory printout or a clear scan that shows the units, the reference range and the date of collection.
If you have a series of results over time, present them in order. A single high value is less informative than a trend showing whether a level is falling, stable or rising. If a dynamic test was performed, such as a suppression or stimulation test, include the protocol and the full result set rather than only the conclusion.
Do not stop or change hormone replacement, steroid medication or suppressive therapy before a review. The treating clinician decides whether any adjustment is appropriate, and abrupt changes can be unsafe. Your role is to provide accurate records so that decision can be made with full information.
Imaging and visual assessment: what the surgical team needs to see
Imaging for pituitary tumours is read against previous scans, and the written report alone can leave the receiving team guessing about what actually changed. If you can provide the images themselves, not only the report, the team can compare tumour size and position directly. If images are not available, send the reports with the date, the modality, the slice thickness if stated, and whether contrast was used.
Visual assessment matters because the optic nerves pass close to the pituitary region. If you have had visual field testing or a formal ophthalmology review, include the date, the method and the result. Your own impression that 'my vision is fine' is not a substitute for a documented assessment, and a documented assessment is not a substitute for the receiving team's own examination.
When you describe imaging and visual results, state what changed and when. 'MRI in March 2024 showed stable residual tumour compared with 2023' is more useful than 'MRI was done'. If you do not know whether something changed, say so rather than guessing.
One practical point about imaging records: reports from different hospitals may use different measurement conventions, and a tumour measured as 18 mm at one centre and 16 mm at another is not automatically a change in size. Say which scan you are comparing and on what date, and let the receiving clinician decide whether the difference is real.
If a scan was done at a hospital that will not release images to you directly, ask what the release process is and how long it takes. This is an administrative step, not a clinical one, and it is worth starting early because it can hold up a review.
For visual records, the same logic applies. A visual field printout with the date and the testing method is more useful than a sentence saying vision is stable. If you have had several tests, send them in order so the trend is visible.
How endocrine, eye and surgical assessment fit together
Pituitary care crosses endocrinology, ophthalmology and neurosurgery. A surgical review is not a single appointment with one specialist deciding everything in isolation. The endocrine picture informs whether hormone control is adequate and whether medication is still an option. The eye assessment informs whether vision is at risk. The surgical assessment considers whether an operation is technically appropriate and what approach would be used.
For an overseas patient, it is reasonable to ask how these assessments would be coordinated in China: whether they happen on the same visit or across several, who reviews the endocrine results, who performs the visual assessment, and which specialty takes responsibility for ongoing hormone and imaging follow-up after any treatment. These are practical questions about coordination, and the answers depend on the hospital and the individual case.
It is also reasonable to ask who would manage long-term follow-up if you return home. Pituitary disease often requires ongoing hormone monitoring and periodic imaging, and that follow-up needs a clear owner. Ask the receiving team how they would communicate with your local clinicians and what records they would expect to receive.
Preparing a records summary and the next step
Before contacting a hospital or coordination service, prepare a short summary that a clinician can read in a few minutes. It should state the diagnosis, the date of diagnosis, each treatment with its dates, the measured results after each treatment, current medications with doses, current symptoms, and the specific question you want answered. Attach the supporting reports in a logical order.
An initial enquiry can start with a brief summary rather than a complete archive. The team can then explain what additional records would be useful for a particular review. A records-based opinion is not a final treatment decision, and no outcome can be guaranteed; the treating hospital decides suitability after assessing the patient and the records.
If you would like to understand how previous treatment results are reviewed for pituitary tumour surgery in China, you can begin with a free initial case review. The team checks the available diagnosis, records and your main question, identifies missing information and suggests the relevant next step. You can also read more about pituitary tumour surgery to understand the procedure itself.
Sources & scope of this guide
References and official service information relevant to this guide.
This is general planning information and has not been individually reviewed by a doctor. Medical decisions and personal treatment advice come from your treating clinicians.